Subscribe
shutterstock_1335829340_manuel-esteban
manuelesteban / Shutterstock.com
8 April 2019Americas

Sun Pharma takes Pfizer to court over Lyrica

India-based drugmaker Sun Pharma has accused Pfizer of infringing a patent with a new extended-release formulation of Lyrica (pregabalin).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Pfizer and Sun settle Bosulif dispute
6 November 2019   Pfizer and Indian drugmaker Sun Pharmaceuticals have agreed to settle patent litigation over a generic version of Pfizer’s leukaemia drug, Bosulif.
Americas
Pfizer expects $1.9bn loss due to patent expirations
31 July 2018   US-based pharmaceutical company Pfizer today reported an increase in year-on-year revenue for the second quarter but projected nearly a $2 billion loss in 2018 due to patent expirations.
Asia
Pfizer sues Sun Pharma for patent infringement
13 September 2016   Pfizer has sued Indian generic company Sun Pharma for allegedly infringing patents centring on Xeljanz, a treatment for rheumatoid arthritis.


Editor's picks

A step too far? Why Stewart’s approach is dividing opinion
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025

Editor's picks

Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Counsel grapple with AI’s impact on training and critical thinking
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025

More on this story

Americas
Pfizer and Sun settle Bosulif dispute
6 November 2019   Pfizer and Indian drugmaker Sun Pharmaceuticals have agreed to settle patent litigation over a generic version of Pfizer’s leukaemia drug, Bosulif.
Americas
Pfizer expects $1.9bn loss due to patent expirations
31 July 2018   US-based pharmaceutical company Pfizer today reported an increase in year-on-year revenue for the second quarter but projected nearly a $2 billion loss in 2018 due to patent expirations.
Asia
Pfizer sues Sun Pharma for patent infringement
13 September 2016   Pfizer has sued Indian generic company Sun Pharma for allegedly infringing patents centring on Xeljanz, a treatment for rheumatoid arthritis.

More on this story

Americas
Pfizer and Sun settle Bosulif dispute
6 November 2019   Pfizer and Indian drugmaker Sun Pharmaceuticals have agreed to settle patent litigation over a generic version of Pfizer’s leukaemia drug, Bosulif.
Americas
Pfizer expects $1.9bn loss due to patent expirations
31 July 2018   US-based pharmaceutical company Pfizer today reported an increase in year-on-year revenue for the second quarter but projected nearly a $2 billion loss in 2018 due to patent expirations.
Asia
Pfizer sues Sun Pharma for patent infringement
13 September 2016   Pfizer has sued Indian generic company Sun Pharma for allegedly infringing patents centring on Xeljanz, a treatment for rheumatoid arthritis.

More features

Bankruptcy judge approves $305m sale of genetics testing company
Sanofi successfully challenges rare disease patent in Europe
Bayer appoints new head of IP
WATCH: Policy direction—where are we now?
Broad Institute wins appeal to restore CRISPR patent in Europe
BMS faces fresh lawsuit over alleged cancer drug monopoly
WATCH: Synergy in science—navigating the landscape of pharmaceutical collaborations
Boies Schiller Flexner adds three-strong litigation team